An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting | AVESİS

İstanbul Üniversitesi-Cerrahpaşa Akademik Veri Yönetim Sistemi

An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

Atıf İçin Kopyala

Cicin I., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Slim B. A. , ...Daha Fazla

11th European Breast Cancer Conference (EBCC), Barcelona, İspanya, 21 - 23 Mart 2018, cilt.92

Yayın Türü: Bildiri / Özet Bildiri
Cilt numarası: 92
Doi Numarası: 10.1016/s0959-8049(18)30535-5
Basıldığı Şehir: Barcelona
Basıldığı Ülke: İspanya